Karen E. Keller

Elana Araj

Jonathan D. Ball

Scott J. Bornstein

Nathan R. Hoeschen

Kathryn Albanese

Danielle M. Zapata

Bruce M. Wexler

William F. Cavanaugh, Jr.

Daniel M. Silver

Chad J. Peterman

Alexandra M. Joyce

Zhiqiang Liu

Christopher P. Hill

Michael F. Werno

Maliheh Zare

Sarah Spencer

Teva's ANDA filing for generic Edarbyclor sparks a patent clash over formulation claims covering a `pH control agent` vital to hypertension treatment.

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Name	Ratings
Azurity Pharmaceuticals Inc	L3 C
Takeda Pharmaceutical Co Ltd	L5 A
Arbor Pharmaceuticals LLC	-- -- --

Name	Ratings
McCarter & English LLP	L5 A
Daniel M. Silver	L5 A
Alexandra M. Joyce	L5 C
Maliheh Zare	-- -- --
Paul Hastings LLP	L4 D
Bruce M. Wexler	L5 A
Chad J. Peterman	L4 A
Christopher P. Hill	L1 A
Michael F. Werno	-- -- --
Sarah Spencer	-- -- --
Patterson Belknap Webb & Tyler LLP	L3 B
William F. Cavanaugh, Jr.	L4 A
Zhiqiang Liu	L3 B

Name	Ratings
Greenberg Traurig LLP	L5 D
Scott J. Bornstein	L5 E
Jonathan D. Ball	L4 E
Elana Araj	L3 E
Kathryn Albanese	L2 C
Danielle M. Zapata	-- -- --
Shaw Keller LLPLocal	L4 D
Nathan R. Hoeschen	L5 B
Karen E. Keller	L5 E

1:23-cv-01080

Azurity Pharma Inc v. Teva Pharma Inc